Responses
Clinical/translational cancer immunotherapy
Original research
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
Compose a Response to This Article
Other responses
No responses have been published for this article.